Annual Information Update

RNS Number : 1385Q

Oxford Biomedica PLC

03 April 2009

 



For Immediate Release

3 April 2009

Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')

Annual Information Update for the Twelve Months to 3 April 2009

Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority. 

1.     Announcements made via a Regulatory Information Service

Date	Announcement
15 April 2008	Notice of changes in board composition to be effective July 2008
30 April 2008	Total voting rights update
9 May 2008	Interim management statement
9 May 2008	Annual general meeting statement
16 May 2008	Notice of TroVax clinical data presentation
19 May 2008	Corporate presentation at Rodman & Renshaw healthcare conference
27 May 2008	Corporate presentation at FBR capital markets conference
30 May 2008	Total voting rights update
30 May 2008	Blocklisting interim review
2 June 2008	TroVax clinical data presentation
24 June 2008	Corporate presentation at Jefferies healthcare conference
1 July 2008	Board changes: retirement of Chairman and Chief Scientific Officer, appointment of new Chief Scientific Officer, changes to roles of three directors
1 July 2008	Response to Bavarian Nordic US patent infringement action
11 July 2008	Update on TroVax phase III clinical trial in renal cancer
14 July 2008	Update on planned TroVax clinical trial in colorectal cancer
15 July 2008	Further update on TroVax phase III clinical trial in renal cancer
28 July 2008	Board change: appointment of non-executive director
15 August 2008	Rejection of indicative approach by GeneThera Inc.
15 August 2008	Rule 2.10 announcement
18 August 2008	Holding(s) in Company
27 August 2008	Notice of interim results
29 August 2008	Interim results
29 August 2008	Board change: resignation of CEO, acting CEO appointed
9 September 2008	ProSavin clinical data
10 September 2008	Directors' interests in shares
18 September 2008	Corporate presentation at UBS life sciences conference
7 October 2008	Update on TroVax phase III clinical trial in renal cancer
13 October 2008	Board change: permanent CEO confirmed
14 October 2008	Holding(s) in Company
24 October 2008	TroVax clinical data presentation
7 November 2008	Corporate presentation at Rodman & Renshaw healthcare conference
14 November 2008	Presentation of ProSavin clinical data
18 November 2008	Interim management statement
19 November 2008	ProSavin clinical data
28 November 2008	Blocklisting interim review
12 January 2009	Dismissal of Bavarian Nordic US patent infringement action
27 January 2009	Response to re-filed US patent infringement action
5 February 2009	Issue of shares re. investment in StarGen development
25 February 2009	Notice of results
27 February 2009	Total voting rights update
4 March 2009	Holding(s) in Company
10 March 2009	Holding(s) in Company
12 March 2009	Preliminary results for 2008
20 March 2009	Holding(s) in Company
23 March 2009	Holding(s) in Company
25 March 2009	Directors' interests in shares and share options
31 March 2009	Annual report & accounts and AGM notification
3 April 2009	Annual information update

Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at www.londonstockexchange.com  and on the Oxford BioMedica website at http://www.oxfordbiomedica.co.uk  

2. Documents filed with Companies House

Date	Document Type	Description
21 May 2008	AGM Special Business	AGM minutes
1 July 2008	288b Resignation of a director	Dr Peter Johnson
1 July 2008	288b Resignation of a director	Dr Susan Kingsman
1 July 2008	288a Appointment of director	Dr Stuart Naylor
1 August 2008	288a Appointment of director	John Dawson
28 August 2008	288b Resignation of a director	Dr Michael McDonald
20 September 2008	363s Annual Return	Annual return
11 February 2009	88(2) Return of Allotment of shares	Allotment 215,445 1p Ord.
11 February 2009	88(2) Return of Allotment of shares	Allotment 2,209,042 1p Ord.

Copies of documents filed at Companies House can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk  

3. Documents published or sent to shareholders or filed with the UKLA Viewing Facility

Date	Description
16 September 2008	Interim Report for 6 months to 30 June 2008
31 March 2009	Annual report for the year ended 31 December 2008

Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office: 

This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person. 

Oxford BioMedica plc

Medawar Centre

Robert Robinson Avenue

The Oxford Science Park

Oxford 

OX4 4GA

3 April 2009

 

END

 

 

AIUEXLFBKZBBBBE